Berger A, Drosten Ch, Doerr H W, Stürmer M, Preiser W
Institute for Medical Virology, Johann Wolfgang Goethe University Hospital, Paul Ehrlich-Street 40, D-60596 Frankfurt a. M., Germany.
J Clin Virol. 2004 Jan;29(1):13-22. doi: 10.1016/j.jcv.2003.09.011.
An acute and often severe respiratory illness emerged in southern China in late 2002 and rapidly spread to different areas of the Far East as well as several countries around the globe. When the outbreak of this apparently novel infectious disease termed severe acute respiratory syndrome (SARS) came to an end in July 2003, it had caused over 8000 probable cases worldwide and more than 700 deaths. Starting in March 2003, the World Health Organization (WHO) organised an unprecedented international effort by leading laboratories working together to find the causative agent. Little more than one week later, three research groups from this WHO-coordinated network simultaneously found evidence of a hitherto unknown coronavirus in SARS patients, using different approaches. After Koch's postulates had been fulfilled, WHO officially declared on 16 April 2003 that this virus never before seen in humans is the cause of SARS. Ever since, progress around SARS-associated coronavirus (SARS-CoV) has been swift. Within weeks of the first isolate being obtained, its complete genome was sequenced. Diagnostic tests based on the detection of SARS-CoV RNA were developed and made available freely and widely; nevertheless the SARS case definition still remains based on clinical and epidemiological criteria. The agent's environmental stability, methods suitable for inactivation and disinfection, and potential antiviral compounds have been studied, and development of vaccines and immunotherapeutics is ongoing. Despite its grave consequences in humanitarian, political and economic terms, SARS may serve as an example of how much can be achieved through a well-coordinated international approach, combining the latest technological advances of molecular virology with more "traditional" techniques carried out to an excellent standard.
2002年末,一种急性且往往较为严重的呼吸道疾病在中国南方出现,并迅速蔓延至远东不同地区以及全球多个国家。2003年7月,这场被称为严重急性呼吸综合征(SARS)的明显新型传染病疫情结束时,已在全球造成8000多例疑似病例和700多人死亡。从2003年3月开始,世界卫生组织(WHO)组织了一场前所未有的国际行动,顶尖实验室携手合作寻找病原体。仅仅一周多后,来自这个WHO协调网络的三个研究小组同时采用不同方法,在SARS患者中发现了一种此前未知的冠状病毒的证据。在满足科赫法则后,WHO于2003年4月16日正式宣布,这种从未在人类中见过的病毒是SARS的病因。从那时起,围绕严重急性呼吸综合征相关冠状病毒(SARS-CoV)的研究进展迅速。在获得首个毒株后的几周内,其完整基因组就被测序。基于检测SARS-CoV RNA的诊断测试被开发出来并免费广泛提供;不过,SARS的病例定义仍然基于临床和流行病学标准。该病原体的环境稳定性、适合灭活和消毒的方法以及潜在的抗病毒化合物都已得到研究,疫苗和免疫疗法的研发也在进行中。尽管SARS在人道主义、政治和经济方面造成了严重后果,但它可以作为一个例子,说明通过协调良好的国际方法,将分子病毒学的最新技术进展与执行到卓越标准的更“传统”技术相结合,能够取得多大的成就。